Effect of L-dopa, adrenergic  -blockers and anticholinergic agents on the tremorine-tremor in mice.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000605:Amino Alcohols / Q000627:therapeutic use*; D000818:Animals; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D006834:Hydrazines / Q000627:therapeutic use; D007545:Isoproterenol / Q000627:therapeutic use; D008297:Male; D051379:Mice; D010276:Parasympatholytics / Q000627:therapeutic use*; D010627:Phenethylamines / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D013237:Stereoisomerism; D013565:Sympatholytics / Q000627:therapeutic use*; D014191:Tranylcypromine / Q000627:therapeutic use; D014202:Tremor / Q000139:chemically induced / Q000517:prevention & control*; D014203:Tremorine
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D004338:Drug Combinations; D006834:Hydrazines; D010276:Parasympatholytics; D010627:Phenethylamines; D010880:Piperidines; D013565:Sympatholytics; D014191:Tranylcypromine; D004295:Dihydroxyphenylalanine; D011433:Propranolol; D007545:Isoproterenol; D014203:Tremorine